ArticlePloS one2009
Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- A Reassessment of Genes Modulating Aging in Mice Using Demographic Measurements of the Rate of Aging.Genetics · 2018Pooled it
- p53 prophylactic therapy for cancer prevention.Cell death and differentiation · 2025Article
- Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models.Cancer research communications · 2024Article
- Review
- Reducing the aneuploid cell burden - cell competition and the ribosome connection.Disease models & mechanisms · 2022Review
- A Unique Spectrum of Spontaneous Tumors inCells · 2022Article
- A Transcriptionally Distinct Subpopulation of Healthy Acinar Cells Exhibit Features of Pancreatic Progenitors and PDAC.Cancer research · 2021Article
- Is There an Interconnection between Epithelial-Mesenchymal Transition (EMT) and Telomere Shortening in Aging?International journal of molecular sciences · 2021Review
- p53 and Tumor Suppression: It Takes a Network.Trends in cell biology · 2021Review
- Robust p53 Stabilization Is Dispensable for Its Activation and Tumor Suppressor Function.Cancer research · 2021Article
- p53 deficiency triggers dysregulation of diverse cellular processes in physiological oxygen.The Journal of cell biology · 2020Article
- Emerging mechanisms of cell competition.Nature reviews. Genetics · 2020Review
- How the Other Half Lives: What p53 Does When It Is Not Being a Transcription Factor.International journal of molecular sciences · 2019Review
- New Insights into the Role of Epithelial⁻Mesenchymal Transition during Aging.International journal of molecular sciences · 2019Review
- An integrative theory for cancer (Review).International journal of molecular medicine · 2019Review
- Two-Step Senescence-Focused Cancer Therapies.Trends in cell biology · 2018Review
- Deciphering p53 signaling in tumor suppression.Current opinion in cell biology · 2018Review
- Deconstructing networks of p53-mediated tumor suppression in vivo.Cell death and differentiation · 2018Review
- Genetically engineered mouse models for studying radiation biology.Translational cancer research · 2017Article
- Sustained p16Oncogene · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inactivating mutations in the p53 tumor suppressor gene occur often in the progression of human cancers. p53 inhibits the outgrowth of nascent cancer cells through anti-proliferative actions (including induction of apoptosis or senescence). To test p53 tumor suppressor functions in a novel experimental context, we somatically deleted both p53 alleles in multiple tissues of mice at various ages. Mice homozygously deleted for p53 at 3 months of age showed a longer tumor latency compared to mice deleted for p53 at 6 and 12 months of age. These results are consistent with a model in which tissues accumulate oncogenically activated cells with age and these are held in check by wildtype p53. We also deleted p53 before, concurrent with, and after treatment of mice with ionizing radiation (IR). The absence or presence of p53 during IR treatment had no effect on radiation-induced lymphoma latency, confirming that the immediate p53 damage response was irrelevant for cancer prevention. Even the presence of wildtype p53 for up to four weeks post-IR provided no protection against early lymphoma incidence, indicating that long term maintenance of functional p53 is critical for preventing the emergence of a cancer. These experiments indicate that sustained p53 anti-oncogenic function acts as a final or near final line of defense preventing progression of oncogenically activated cells to malignant tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.